With U.S. stock futures drifting slightly lower Wednesday morning, a handful of companies are positioning themselves to grab the spotlight. Here's what's happening:

UiPath Inc. (PATH) got some excellent news after the bell Tuesday. S&P Dow Jones Indices announced that the agentic automation company will join the S&P Midcap 400, replacing Synovus Financial Corp. (SNV) effective before the market opens on January 2, 2026. Index inclusion matters because it typically brings a wave of passive fund buying, and investors clearly liked what they heard. UiPath shares jumped 6.8% to $17.05 in after-hours trading.

Agios Pharmaceuticals Inc. (AGIO) announced that the FDA has approved AQVESME (mitapivat) for treating anemia in adults with alpha- or beta-thalassemia. It's a meaningful regulatory win for the biotech, expanding the drug's approved uses. Despite the positive news, Agios shares fell 1.4% to close at $24.59 on Tuesday during regular trading hours.

Can Fite Biopharma (CANF) disclosed a dramatic 1-for-3,000 reverse share split. That's not a typo—every 3,000 shares become one share. Reverse splits are typically seen as distress signals, and the market responded accordingly. Can Fite Biopharma shares tumbled 28.8% to $0.17 in after-hours trading.

Citius Pharmaceuticals Inc. (CTXR) delivered a pleasant surprise with its fourth-quarter earnings. The company posted a quarterly loss of 11 cents per share, crushing market estimates that called for a loss of 43 cents per share. That's the kind of beat that gets investors excited. Citius Pharmaceuticals shares surged 22.1% to $1.27 in after-hours trading.

Ramaco Resources Inc. (METC) unveiled a $100 million stock repurchase plan, signaling confidence in its valuation. Buyback announcements tend to please shareholders, and this was no exception. Ramaco Resources shares jumped 7.1% to $18.09 in the after-hours session.

As Wednesday's trading gets underway, these names are worth keeping on your radar as the broader market navigates a slightly softer futures backdrop.